Biobase raises pre-seed round for AI clinical-data platform

What's the deal? BiobaseDealroom has a profile for this one. Try Dealroom → has closed a pre-seed round backed by Nina CapitalDealroom has a profile for this one. Try Dealroom →, DigiTx PartnersDealroom has a profile for this one. Try Dealroom →, and the Washington Research FoundationDealroom has a profile for this one. Try Dealroom →. All three specialise in health and life-sciences technology.

What's the endgame? The company is building an AI-based operating system for managing and using clinical data. Its platform aims to connect health systems, labs, and biobanks with pharmaceutical firms, biotech companies, and AI developers.

What's the money for? Biobase will use the funding to accelerate development of that platform, which it says automates processes and streamlines data workflows. The company also plans to add strategic partners and expand its reach.

Why now? The round adds investors experienced in digital health, biomedical innovation, and technology transfer to Biobase's cap table at an early stage. The company frames the deal as a vote of confidence in its plan to build shared infrastructure across healthcare and life sciences.

The signal: Investor appetite continues for tools that make clinical data usable for drug research and AI. Biobase is betting that connecting fragmented data sources — securely and at scale — is the bottleneck worth solving.

Read more: Capital Riesgo